However, in our study, we analyzed the mutations of genes with high mutation frequency (mutation rate >5%) in NDB patients and found that STK11 mutation has no significant relationship with the prognosis of NSCLC patients with NDB who received ICBs. Here, STK11 is linked to non-small cell lung carcinoma.